135 related articles for article (PubMed ID: 10901296)
1. Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure.
Keskin O; Bahar I; Jernigan RL; Beutler JA; Shoemaker RH; Sausville EA; Covell DG
Anticancer Drug Des; 2000 Apr; 15(2):79-98. PubMed ID: 10901296
[TBL] [Abstract][Full Text] [Related]
2. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
[TBL] [Abstract][Full Text] [Related]
3. Anticancer activity of natural cytokinins: a structure-activity relationship study.
Voller J; Zatloukal M; Lenobel R; Dolezal K; Béres T; Krystof V; Spíchal L; Niemann P; Dzubák P; Hajdúch M; Strnad M
Phytochemistry; 2010 Aug; 71(11-12):1350-9. PubMed ID: 20553699
[TBL] [Abstract][Full Text] [Related]
4. Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
Huang R; Wallqvist A; Covell DG
J Med Chem; 2006 Mar; 49(6):1964-79. PubMed ID: 16539384
[TBL] [Abstract][Full Text] [Related]
5. NCI's anticancer drug screening program may not be selecting for clinically active compounds.
Brown JM
Oncol Res; 1997; 9(5):213-5. PubMed ID: 9306428
[TBL] [Abstract][Full Text] [Related]
6. Data mining the NCI cancer cell line compound GI(50) values: identifying quinone subtypes effective against melanoma and leukemia cell classes.
Marx KA; O'Neil P; Hoffman P; Ujwal ML
J Chem Inf Comput Sci; 2003; 43(5):1652-67. PubMed ID: 14502500
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antitumor cytotoxicity evaluation of pyrido[4,3,2-de]quinolines and isoquinolino[6,5,4,3-cde]quinolines.
Ding Q; Jia G; Lown JW
Anticancer Drug Des; 2000 Apr; 15(2):99-108. PubMed ID: 10901297
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, structural characterization, and in vitro antitumor activity of novel N-(6-chloro-1,1-dioxo-1,4,2-benzodithiazin-3-yl)arylsulfonamides.
Brzozowski Z; Saczewski F; Sławiński J; Bednarski PJ; Grünert R; Gdaniec M
Bioorg Med Chem; 2007 Apr; 15(7):2560-72. PubMed ID: 17306551
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and antitumor cytotoxicity of novel bis-benzimidazoles.
Singh AK; Lown JW
Anticancer Drug Des; 2000 Aug; 15(4):265-75. PubMed ID: 11200502
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I).
Caruso F; Rossi M; Tanski J; Pettinari C; Marchetti F
J Med Chem; 2003 Apr; 46(9):1737-42. PubMed ID: 12699391
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
12. Semisynthesis and in vitro anticancer activities of andrographolide analogues.
Jada SR; Subur GS; Matthews C; Hamzah AS; Lajis NH; Saad MS; Stevens MF; Stanslas J
Phytochemistry; 2007 Mar; 68(6):904-12. PubMed ID: 17234223
[TBL] [Abstract][Full Text] [Related]
13. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
Huang R; Wallqvist A; Thanki N; Covell DG
Pharmacogenomics J; 2005; 5(6):381-99. PubMed ID: 16103895
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, crystal structure and anticancer activity of novel derivatives of ethyl 1-(4-oxo-8-aryl-4,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazin-3-yl)formate.
Sztanke K; Rzymowska J; Niemczyk M; Dybała I; Kozioł AE
Eur J Med Chem; 2006 Apr; 41(4):539-47. PubMed ID: 16545495
[TBL] [Abstract][Full Text] [Related]
15. Discovering novel 3-nitroquinolines as a new class of anticancer agents.
Li HH; Huang H; Zhang XH; Luo XM; Lin LP; Jiang HL; Ding J; Chen KX; Liu H
Acta Pharmacol Sin; 2008 Dec; 29(12):1529-38. PubMed ID: 19026174
[TBL] [Abstract][Full Text] [Related]
16. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action.
Huang R; Wallqvist A; Covell DG
Biochem Pharmacol; 2005 Apr; 69(7):1009-39. PubMed ID: 15763539
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of 11-substituted 6-aminobenzo[c]phenanthridine derivatives, a new class of antitumor agents.
Kock I; Heber D; Weide M; Wolschendorf U; Clement B
J Med Chem; 2005 Apr; 48(8):2772-7. PubMed ID: 15828815
[TBL] [Abstract][Full Text] [Related]
18. A structural analysis of the differential cytotoxicity of chemicals in the NCI-60 cancer cell lines.
Chakravarti SK; Klopman G
Bioorg Med Chem; 2008 Apr; 16(7):4052-63. PubMed ID: 18243714
[TBL] [Abstract][Full Text] [Related]
19. Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
Bolognese A; Correale G; Manfra M; Lavecchia A; Mazzoni O; Novellino E; La Colla P; Sanna G; Loddo R
J Med Chem; 2004 Feb; 47(4):849-58. PubMed ID: 14761187
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, X-ray crystal structures, stabilities, and in vitro cytotoxic activities of new heteroarylacrylonitriles.
Saczewski F; Reszka P; Gdaniec M; Grünert R; Bednarski PJ
J Med Chem; 2004 Jun; 47(13):3438-49. PubMed ID: 15189040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
